Table 4.

(A) Demographic and (B) clinical features of an analyzed cohort.

	iPD (n = 103)		drug-naïve iPD (n = 7)		Control (CN) (n = 93)		AD (n = 28)		n (Sum)
	Male	Female	Male	Female	Male	Female	Male	Female
(A) Demographic features of analysed cohort
n	65	38	6	1	49	44	8	20	231
Median age years (SD)	65 (9.7)	67.5 (7.9)	66.5 (7.8)	48 (−)	76 (9.5)	74 (8.6)	75.5 (7.9)	73 (8.5)	NA

	Age at assessment	Age at onset of PD symptoms	Duration of disease	Total levodopa equivalent	MDS-UPRDS I	MDS-UPDRS II	MDS-UPRDS III	MDS-Part IV	MDS-UPDRS total	Schwab & England	Hohn & Yahr
(B) Clinical features of analysed cohort
Number of values	104	104	104	103	103	103	104	104	104	104	104
Minimum	41	29	0	0	1	1	0	0	11	0	0
25% Percentile	60	52	3	450	7	5	12	0	31	80	2
Median	66	58	6	750	10	8	20	3	43.5	90	2
75% Percentile	71	63.8	10	1178	15	14	32.8	6	61	90	2
Maximum	87	80	31	3351	31	31	68	17	136	100	5
Range	46	51	31	3351	30	30	68	17	125	100	5
10% Percentile	54	43	2	40	4.4	3	7	0	22	75	1
90% Percentile	75	71.5	13	1500	18	19	43	9.5	80.5	100	3
95% CI of median
Lower confidence limit	63	56	5	675	9	7	16	2	37	90	2
Upper confidence limit	68	61	8	900	13	10	24	4	52	90	2
Mean	65	57.9	7.1	868.1	11.3	10.1	22.9	3.7	47.8	84.6	2
Std. deviation	8.9	10.1	5.2	632.9	5.8	6.4	14.2	3.8	23.7	14.1	0.8
Std. errror of mean	0.9	1	0.5	62.4	0.6	0.6	1.4	0.4	2.3	1.4	0.1
Lower 95% CI of mean	63.3	55.9	6.1	744.4	10.2	8.8	20.2	3	43.2	81.9	1.8
Upper 95% CI of mean	66.7	59.9	8.1	991.8	12.4	11.3	25.7	4.5	52.4	87.4	2.1